Teva launches another MS trial for laquinimod; MultiVir sets out for $60M IPO;

@FierceBiotech: AstraZeneca loans its oncology star to Celgene, recruits Innate in a PD-L1 deal spree. News | Follow @FierceBiotech

@JohnCFierce: Aerie shares crushed after glaucoma therapy flops in PhIII. Story | Follow @JohnCFierce

> Teva ($TEVA) and partner Active Biotech kicked off a Phase II study of their laquinimod in a Phase II study in primary progressive multiple sclerosis. More

> The FDA granted a priority review for AbbVie's ($ABBV) cocktail treatment for genotype 4 hepatitis C. Item

> Gene therapy biotech MultiVir set terms for a $60 million IPO. Story

Medical Device News

@FierceMedDev: Low-cost smart syringe shoots for reduced disease transmission. News | Follow @FierceMedDev

@VarunSaxena2: Ahead of Apple Watch launch, hearing aid company reveals its app development experience. Story | Follow @VarunSaxena2

@EmilyWFierce: Medical device makers such as $GE, $ABT, $BSX and $JNJ forming the first industry trade group in #Asia. Pharmalot story | Follow @EmilyWFierce

> Bard's Lutonix drug-coated balloons help lift Q1 earnings. News

> FDA deems all 4,000+ of troubled Maquet's left atrial appendage closure devices potentially deadly, announces major recall. More

Pharma News

@FiercePharma: Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. News | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10. Story | Follow @CarlyHFierce

> BMS scores positive EMA opinion for Opdivo in advanced melanoma patients. More

> AstraZeneca sales retreat in its effort to achieve huge growth by 2023. News

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.